Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  epratuzumab
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-12 of 12 for your search:
Start Over
Phase I/II Study of Immunotherapy with Humanized Monoclonal Antibody LL2 in Patients with Recurrent Non-Hodgkin's Lymphoma (Summary Last Modified 03/1999)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: UNMC-289-97, IM-h-LL2-01, NCI-V97-1353
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 2 to 31
Sponsor: NCI, Other
Protocol IDs: ADVL04P2, NCI-2011-01624, COG-ADVL04P2, CDR0000396777, U10CA098543, NCT00098839
Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 16 to 65
Sponsor: Other
Protocol IDs: 6125, NCT01279707
Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: BRD 08/12-H, NCT01354457
Phase II Study of Epratuzumab and Rituximab in Patients With Refractory or Recurrent Low-Grade CD20-Positive B-Cell Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0109058, AMGEN-20010138, NCT00054379
Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NCCTG-N0489, NCI-2012-02685, CDR0000459932, N0489, NCT00301821
Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000572604, U10CA031946, CALGB-50701, NCT00553501
S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 16 and over
Sponsor: NCI, Other
Protocol IDs: S0910, U10CA032102, SWOG-S0910, NCT00945815
Phase I Pilot Study of 131I-Labeled MOAB LL2 for B-Cell non-Hodgkin's Lymphoma (Summary Last Modified 06/95)
Phase: Phase I
Type: Treatment
Status: Closed
Age: over 18
Sponsor:
Protocol IDs: UCHSC-91264, NCI-V91-0216
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: LYMNHL0031, 200114861, 77550, CA09287, CA111827, NCT00398372
Start Over